Objective To observe the efficacy and side effect of olanzapine combined with tropisetron, dexamethasone for the pre-vention of highly emetogenic chemotherapy-induced nausea and vomiting ( CINV) . Methods A total of 78 patients with highly emetogen-ic single day chemotherapy were randomly divided into two groups:trial group ( olanzapine combined with tropisetron, dexamethasone n=40) and control group (Tropisetron Combined with Dexamethasone n=38). The control of acute CINV, delayed CINV and adverse reac-tions were observed. Results The control rates of acute vomiting in trial group and control group were 87. 5% vs 81. 6%, 65. 0% vs 57. 9% in acute nausea, 75. 0% vs 52. 6% in delayed vomiting, 32. 5% vs 13. 2% in delayed nausea. The trial group was better than the control group in delayed vomiting and delayed nausea which there was difference between them (P < 0. 05). There was no statistical differ-ence between the two groups in the incidence of adverse reactions (P>0. 05). Conclusion Olanzapine combined with tropisetron, dexa-methasone for the prevention was significantly better than tropisetron combined with dexamethasone in the control of delayed CINV in pa-tients received highly emetogenic chemotherapy.

Objective To analyze the relative factors of bone marrow suppression after chemotherapy with different-dose carboplatin and paclitaxel (TC) on the patients with ovarian cancer.Methods Sixty-two patients with ovarian cancer admitted in Beijing Obstetrics and Gynecology Hospital from January 2002 to December 2007, using TC regimen ,a total of 196 cycles of chemotherapy ,were divided into two groups by the doses of carboplatin [area under concentration-time curve(AUC) 4 -6 for low-dose,AUC >6 -7 for hight-dose, the carboplatin dose calculated with AUC] or by the doses of paclitaxel (135 -< 150 mg/m2 low-dose,150 - 175 mg/m2 hight-dose). After each TC cycle, the routine blood was test to determine the graduation of the marrow suppression, and then the correlation factors were analyzed with logistic regression. Results (1) The occurrence rate of bone marrow suppression:there were 159 cycles (81.1%) grade 0 - Ⅱ bone marrow suppression, while 37 cycles (18.9%) of grade Ⅲ - Ⅳ. (2) Factors related to bone marrow suppression:the results shown that there were not related to bone marrow suppression,which incluced cellular differentiation, tumor type, height, weight and paclitaxel dose(P>0.05). While,the different cycle, age, the later stages of tumor, serum creatinine concentration, endogenous creatinine clearance rate, AUC values were the relative factors of bone marrow suppression(P =0.000,0.000,0.018,0.033,0.001,0.000). Seven variables were conducted into the logistic regression and the results shown that the different cycles, the age, AUC grades were independent risk factors (P = 0.030,0.043,0.009).(3) When low-dose of paclitaxel was given, the occurrence of bone marrow suppression was related to the carboplatin dose AUC. The higher AUC values for carbopaltin were chosen, the higher of severe bone marrow suppression would happen. (4/14 vs 0,P=0.015). When the dose of high grade of paclitaxel was given, the occurrence of bone marrow suppression in cases with hight-dose carboplatin was statistically significant than that in cases treated with low-dose carboplatin [45.7%(16/35) vs 13.7% (17/124), P=0.000]. Conclusions The independent risk factors of myelosuppression after chemotherapy with TC regime on the patients with ovarian cancer including the cycles, age and AUC values. The carboplatin dose calculating with AUC is related to the occurrence of bone marrow suppression, the higher AUC values for carbopaltin would chosen,the higher of severe bone marrow suppression would be happen.

ObjectiveTo explore the ability of inhibition resistibility of multiple displacement amplification (MDA)in samples with inhibitors. To explain the application and value of MDA in forensic medicine by comparing with using magnetic beads methods(MBM)to purify sample.MethodsDifferent concentra-tions of hemoglobin and humid acid(HA)mixed with DNA samples and then divided the samples into MDA group, MBM group and control group.D3S1358locus was amplified and detected by polyacry-lamide gel electrophoresis detection system and AmpF?STR? IdentifilerTM Plus Kit-capillary electrophore-sis detection system.ResultsWhen hemoglobin concentrations exceed 1 ng/μL or HA concentrations ex-ceed 0.1 ng/μL, amplification products could not be obtained by single-locus system in control group. When hemoglobin concentration exceeds 100 ng/μL or HA concentrations exceed 1 ng/μL, the samples could not be amplified by MBM. Inhibitors in different concentrations were amplified successfully in MDA group without any influence from inhibitors.ConclusionMDA has the capability to remove the inhibi-tion of hemoglobin and HA, which is better than MBM and has a certain value in forensic practices.

Child ; Evidence-Based Medicine ; Glomerulonephritis, IGA ; diagnosis ; therapy ; Guidelines as Topic ; Humans

Salcalcitonin was used to treat 36 patients who suffer from bone pain,17 men and 19 women with the average age of 54 years old, the oldest one is 72 and the youngest is 39 Salcalcitonin 50 IU was sprayed through each nose hole 2 to 3 times every day for 5 to 7 days, the results showed that the effects of Salcalcitonin in treating bone pain cases are significant and there were 13 effective cases and 18 active cases respectively. The total effective ratio is 86.1%.

Objective To observe the early efficacy and safety of combined sequential administration of lamivudine and interferon alfa-2b in patients with hepatitis Be antigen (HBeAg)-positive chronic hepatitis B. Methods 71 patients were divided into combined therapy growp (23 eases),interferon group (27 cases) and lamivudine group (21 cases).patients in the first group were given sequential combination treatment with of lamivudine monotherapy for nine weeks followed by lamivudine plus interferon alfa-2b for 15 weeks while patients in the interferon group and Lamivudine group received interferon alfa-2b monotherapy and lamivudine respectively. Results At 24weeks, 43.37% of the patients who received sequential combination treatment and 33.33% of those who received interferon alfa-2b monotherapy had HBeAg seroconversion,which is higher than those who received lamivudine monotherapy(9.52%, P0.05). The normolization rates of ALT in combining group , interferon group and Lamivudine group were 60.87%, 51.85% and 19.04% respectively(P

BACKGROUND:Previous studies have shown that the survival state of oral mucosal cels directly is directly affected by the nutritional status of the body, therefore, it may be a good indicator of the surgical nutritional status. But whether this index also influences surgical trauma stimulus is stil unclear. OBJECTIVE: To observe the effect of breast augmentation with silicone implants on the survival status of oral mucosal cels. METHODS: Thirty-two female patients scheduled for breast augmentation with silicone implants, including 13 cases of reproductive history and 19 cases of non-reproductive history, aged 23-45 years old. Sub-G1 peak method and Ki-67 were used to detect the proliferation and apoptosis rates of oral mucosa cels before and after breast augmentation with silicone implants for statistical comparisons. RESULTS AND CONCLUSION:Al the 32 cases successfuly completed breast augmentation with silicone implants, and no serious adverse events occurred perioperatively. The oral mucosa cel apoptosis and proliferation rates were (27.3±6.2)% and (27.8±5.8)% before breast augmentation, and (27.8±5.8)% and (20.2±7.7)% after breast augmentation. There was no difference before and after breast augmentation (P > 0.05). These findings indicate that the proliferation and apoptosis of human oral mucosa cels cannot be significantly by breast augmentation-related trauma, and the survival state of oral mucosa cels has some value to assess the nutritional state of breast augmentation recipients.

The chronic B-cell antigen receptor (BCR) pathway plays an important role in malignant proliferation of B-cell lymphoma.Several tyrosine kinase inhibitors have shown impressive anti-tumor activity in relapsed and refractory B-cell non-Hodgkin lymphoma.This review discussed essential tyrosine kinases in BCR signaling pathway and present data from clinical usage of these related novel target agents.

This article focuses on the rapidly evolving understanding of the molecular pathogenetic mechanisms of the bcr-abl-negative myeloproliferative neoplasms (MPN) [myeloproliferative disorders (MPD)],such as polycythemia vera (PV),essential thrombocythemia (ET),and primary myelofibrosis (MF).The amplify therapies were reviewed and IFN-α is an effective agent for these MPN (MPD).Also,the article emphasize once again avoidance MPN and select MPD for such chinese patients.

BACKGROUND:Carbon-fiber-reinforced polymer energy-storing transtibial prostheses are mature and ideal substitutes for professional disable athletes to increase performance.
OBJECTIVE:By discussing the update application and study of the carbon-fiber-reinforced polymer energy-storing transtibial prosthesis and understanding the characteristics of applying transtibial prostheses in different sports program, to provide a useful reference for the design of athletes prostheses.
METHODS:A computer-based search of PubMed and VIP databases was performed for articles related to carbon-fiber-reinforced polymer energy-storing transtibial prostheses published from January 1985 to December 2012. The keywords were“CFRP, energy-storing prosthesis, between-knee (transtibial) prosthesis, disable athletes”in English and Chinese, respectively.
RESULTS AND CONCLUSION:Currently, we focus on the gait analysis, energy cost and stiffness analysis of athletes who wear carbon-fiber-reinforced polymer energy-storing transtibial prostheses. Studies have demonstrated that carbon-fiber-reinforced polymer energy-storing transtibial prostheses have more advantages over traditional prostheses, but have predominantly disadvantages over able-bodied persons. Thus, there are many difficulties in the clinical application of building carbon-fiber-reinforced polymer energy-storing transtibial prostheses based on the characteristics of athletes’ body status and sports programs.